GH Research (NASDAQ:GHRS) Earns “Buy” Rating from HC Wainwright

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $40.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 366.74% from the stock’s previous close.

Separately, Canaccord Genuity Group reduced their target price on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th.

GH Research Stock Down 4.6 %

Shares of GHRS opened at $8.57 on Friday. GH Research has a fifty-two week low of $5.50 and a fifty-two week high of $14.99. The company’s fifty day moving average is $8.44 and its two-hundred day moving average is $9.19. The firm has a market cap of $445.88 million, a PE ratio of -10.85 and a beta of 0.84.

Hedge Funds Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP boosted its stake in GH Research PLC (NASDAQ:GHRS) by 19.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,966,726 shares of the company’s stock after acquiring an additional 656,163 shares during the period. GH Research accounts for 16.7% of Lynx1 Capital Management LP’s portfolio, making the stock its 3rd largest position. Lynx1 Capital Management LP owned approximately 7.62% of GH Research worth $46,252,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).